Trial record 1 of 1 for:    R668-AD-0914
Previous Study | Return to List | Next Study

Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis

This study has been completed.
Sponsor:
Collaborator:
Sanofi
Information provided by (Responsible Party):
Regeneron Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01259323
First received: December 10, 2010
Last updated: October 2, 2012
Last verified: October 2012